NASDAQ:SNDX

Syndax Pharmaceuticals Stock Insider Trading

etoro logo Buy SNDX
*Your capital is at risk
$22.89
-0.720 (-3.05%)
At Close: Jul 13, 2026

Syndax Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -25.83. In total, the insiders bought 4.23M and sold 643.67K SNDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-25.83
Buy 4.23M shares
Sell 643.67K shares
70% Buy Activity
Strong Negative Correlation
Sell Signal Medium Confidence
Jul 08, 2026

Analysis Breakdown:

  • Supported by a negative Insider Power Score of -25.83.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jul 08, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 32 375
Value: $784.8K
Jul 08, 2026
Buy
Common Stock
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 32 375
Value: $206.6K
Jul 08, 2026
Buy
Stock Option (Right to buy)
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 32 375
Value: $206.6K
Jun 12, 2026
Buy
Stock options (Right to buy)
M-Exempt
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 31 235
Value: $431.7K
Jun 12, 2026
Buy
Common Stock
M-Exempt
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 31 235
Value: $431.7K
Jun 12, 2026
Sell
Common Stock
S-Sale
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 31 235
Value: $566.6K
Jun 11, 2026
Sell
Common Stock
S-Sale
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 34 280
Value: $617.0K
Jun 11, 2026
Buy
Common Stock
M-Exempt
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 22 515
Value: $311.2K
Jun 01, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 6 847
Value: $130.0K
Jun 01, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 177
Value: $22.4K
Feb 09, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 3 410
Value: $71.7K
Feb 09, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 17 159
Value: $360.8K
Feb 06, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 7 412
Value: $152.8K
Feb 06, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 2 082
Value: $42.9K
Feb 04, 2026
Buy
Common Stock
A-Award
Legault Pierre
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Common Stock
A-Award
Rizo Aleksandra
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Common Stock
A-Award
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 36 000
Value: $735.5K
Feb 04, 2026
Buy
Common Stock
A-Award
Huber Martin H. Jr.
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Stock Options (Right to buy)
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 118 000
Value: $2.41M
Feb 04, 2026
Buy
Common Stock
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 73 000
Value: $1.49M
Feb 04, 2026
Buy
Stock Options (Right to buy)
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 440 000
Value: $8.99M
Feb 04, 2026
Buy
Common Stock
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 144 600
Value: $2.95M
Feb 04, 2026
Buy
Common Stock
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 30 750
Value: $628.2K
Feb 04, 2026
Buy
Common Stock
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 21 500
Value: $439.2K
Feb 04, 2026
Buy
Common Stock
A-Award
Jarrett Jennifer
Director
Director 24 000
Value: $490.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
10.58% Jun 29
NMRK
$15.02
0.466% Jun 24
X
XMAX
$8.34
2.40% Jun 24
NESR
$25.07
12.49% Jun 23
CAG
$13.43
6.70% Jun 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE